In the Suboxone case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Reckitt Benckiser’s opioid addiction drug, Suboxone. The proposed class alleges that Reckitt took several actions to suppress competition from generic versions of Suboxone, including reformulating Suboxone into a film (for which generic versions of Suboxone tablets could not be substituted by pharmacists), sabotaging efforts to create a joint REMS program, and filing a baseless citizens petition. Faruqi & Faruqi was appointed co-lead counsel by the Court.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 03/05/2013
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Joseph T. Lukens email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771